Why Geology Decides Between Bioleaching and Cyanide Leaching

Cyanide leaching recovers more than 97% of gold from finely ground free-milling ore. Point that same chemistry at a refractory sulfide ore and recovery can collapse to as little as 30%. Bioleaching, the use of microbes to break down metal-bearing minerals, exists almost entirely inside that gap.

That contrast is the whole investing story in miniature. It is tempting to assume one method has simply won and the other is a legacy relic, but the geology refuses to cooperate with that neat framing.

The question matters right now because financing conditions are tightening around it. Lloyds Banking Group’s 2026 sector statements explicitly condition gold mining finance on compliance with the International Cyanide Management Code or equivalent controls, sodium cyanide has consolidated at $2,160 to $3,196 per metric ton across major markets, and a generation of refractory gold and low-grade copper deposits is moving through feasibility.

Here is what this analysis gives you: a working framework for reading which extraction method a project is likely using, why the geology forces that choice, and what the choice signals about a project’s cost structure, recovery risk, and ESG exposure.

Why ore type decides the method before the engineers do

The instinct is to treat method selection as a corporate decision, a choice between two competing technologies. It rarely is. Ore mineralogy sets the constraint first, and process engineers follow what the geology dictates rather than picking freely between equivalent options.

Start with gold. Oxide and free-milling ores, where the gold sits loose and accessible, respond directly to cyanidation. Modern circuits processing finely ground free-milling ore can recover more than 97% of the contained gold. There is little economic reason to reach for anything more complex.

Refractory sulfide ores are a different geological reality. The gold is physically locked inside sulfide mineral matrices, and cyanide cannot reach it. Direct cyanidation of untreated refractory ore may recover only 30% to 50% of the contained metal.

This is exactly where bioleaching earns its place. Used as a pre-treatment stage, processes such as the South African-developed BIOX oxidise the encapsulating sulfides and expose the gold for subsequent cyanidation. That combination lifts recovery into the 85% to 95% range, with one optimised two-stage biooxidation study reaching 94.1%.

Copper mineralogy splits along a parallel line. Oxide and chalcocite-dominant secondary sulfide deposits are highly amenable to heap bioleaching. Chalcopyrite, the world’s most abundant copper sulfide, resists biological attack by forming passivating surface layers. Under near-identical experimental conditions, chalcocite yields roughly twice the dissolved copper concentration of chalcopyrite over an eight-week period.

A third gold category, carbonaceous refractory ore, complicates both methods. The carbon adsorbs dissolved gold, a phenomenon called preg-robbing, dragging down net recovery regardless of the leaching chemistry chosen.

The practical read for you is simple. A project drilling into refractory sulfide ore and defaulting to direct cyanidation is not just leaving recovery on the table; it is building a financial model on a technical misfit. Check the assumed ore type in a feasibility study before you trust the recovery line above it.

Gold mining cost structures vary dramatically across ore types and processing routes, and the gap between all-in sustaining cost and cash cost line items in a feasibility study often traces directly back to the extraction method the ore body demands.

What bioleaching actually costs, and where cyanide’s price tag surprises

The economics look, at first glance, like a straightforward win for bioleaching. The full picture is a set of trade-offs, and the factor that unsettles the easy conclusion arrives last.

Heap bioleaching configurations demand less upfront infrastructure. Cyanide tank-leach plants using carbon-in-pulp (CIP) or carbon-in-leach (CIL) circuits require detoxification systems, reagent storage, and advanced tailings management. The only publicly available capital-cost benchmark is dated: a circa-2001 analysis found bioleaching capital costs could run roughly 50% below conventional smelting and refining. Treat that as historical context, not a current figure, since direct comparisons to modern mill and flotation circuits for the present period are not publicly available.

On operating costs, cyanide’s recurring reagent bill is the material driver. In late 2025, sodium cyanide contract and spot prices ranged widely across the Americas.

Sodium cyanide supply dynamics add a procurement risk layer that sits above the headline price range: supply chain concentration, shipping constraints, and producer consolidation each influence whether contracted volumes actually arrive at the price modelled in the feasibility study.

Sodium cyanide price range, late 2025 $2,160 per metric ton (Brazil), $2,426 (Argentina), and $3,196 (USA). A material and recurring operating cost that bioleaching largely sidesteps.

Bioleaching substitutes microbial culture inoculation, nutrient addition, and acid management, generally at lower unit cost than continuous cyanide procurement, lime, and activated carbon regeneration.

Here is the cost picture broken into its three moving parts:

• CapEx profile: Bioleaching heap configurations require less upfront infrastructure than CIP/CIL tank plants with their detoxification and tailings systems.
• Reagent OpEx: Cyanide carries a heavy, price-volatile reagent burden; bioleaching’s biological and acid inputs are generally cheaper per unit.
• Kinetics and time-value: This is where the simple advantage frays.

That third factor is the one investor presentations tend to underplay. Bioleaching heap cycles run from several months to over a year. Cyanide tank leaching of equivalent material completes in hours to days.

That difference is not an operational footnote. It ties up metal inventory in the leach circuit far longer, delaying revenue and raising the project’s sensitivity to the discount rate applied in valuation. For anyone modelling net present value, leach-cycle duration is a discount-rate lever that can materially change the NPV of a bioleaching project against a cyanide plant treating the same ore volume.

So when a project economics slide leads with lower CapEx and OpEx for bioleaching, the question to hold in mind is what the extended leach cycle does to the time-value of that recovered metal. The apparent cost advantage and the revenue delay pull in opposite directions.

How bioleaching and cyanide leaching compare on environmental liability and project bankability

Cyanide’s environmental risk is concrete and well documented. It is acutely toxic to aquatic life, birds, and mammals, and historical spills from tailings facilities and pipeline failures have triggered community opposition and, in some cases, revoked social licence.

That risk has hardened into regulation. Under the European Union’s Mining Waste Directive framework, high-strength cyanide solutions face prohibition, and the Czech Republic, Hungary, and Germany have implemented restrictions or bans. A cyanide-dependent project in a tightening jurisdiction carries genuine stranded-asset exposure, though accessible sources indicate no new cyanide-specific legislative bans in the EU, US, Latin America, or Africa post-2024.

The industry’s mitigation is the International Cyanide Management Code, a voluntary standard whose adoption is now broadly expected. It sets performance limits of less than 0.5 ppm cyanide in discharged solutions and targets below 10 ppm in tailings facilities.

Now the pivot. Bioleaching is not environmentally neutral; it has simply traded one liability category for another. Its acute toxicity is lower and public perception more favourable, which can shorten permitting timelines. But spent heaps generate acidic leachate and sulfuric acid, the acid mine drainage problem, and thermophile heap environments develop extreme chemistries with sulfate above 120 g/L and dissolved metals up to 20 g/L. Mismanaged, that is a significant long-term liability even with no cyanide present.

The honest conclusion is that neither method is clean. They are differently risky, and each demands its own due-diligence checklist:

• Cyanide: acute toxicity, spill liability, regulatory ban exposure, and the ongoing cost of Code compliance.
• Bioleaching: acid mine drainage, long-term liner integrity, and water balance management in arid sites.

When ESG mandates become a financing condition

The reason this now sits on the bankability slide, not just the reputation slide, is that lenders have started writing it into terms.

Lloyds Banking Group’s 2026 sector statements explicitly condition gold mining finance on adoption of the Cyanide Code or equivalent controls. That is one named institution, but it sets a market precedent, embedding cyanide risk management directly into capital access rather than leaving it as reputational preference.

Mining capital access conditions have shifted beyond interest rate and commodity price inputs: lender due-diligence frameworks now incorporate process-method risk as a screening variable, with extraction chemistry sitting alongside jurisdiction and management track record as a factor in term-sheet negotiations.

The mirror image applies to bioleaching. Projects may attract preferential financing from funds with strict ESG mandates because of the lower toxicity profile. That advantage is contingent, not automatic: it holds only where acid management standards are demonstrably met.

For you, evaluating gold or copper project debt structures, the task is to identify which environmental liability category the chosen method sits in, then confirm the operator’s provisions actually match that exposure. A tail risk that never appears on the recovery-rate slide can still sink the financing.

Where bioleaching’s technical frontier stalls, and what that means for primary copper projects

Copper heap bioleaching is not speculative. It runs at commercial scale across Chile, the US, Australia, and southern Africa, processing hundreds of millions of tonnes of low-grade ore annually, delivering final copper recoveries of roughly 81% to 84% for chalcocite-bearing ores at 20 to 30 degrees Celsius. That maturity is real, and it distinguishes proven bioleaching from the applications often bundled into optimistic investment narratives.

The frontier stalls at a specific point. Ranked by commercial impact, three barriers separate what works today from what remains genuinely unresolved:

1. Chalcopyrite passivation. Elemental sulfur, jarosite, and secondary phases form inhibiting layers on chalcopyrite surfaces. Commercial-scale recovery benchmarks for chalcopyrite heap bioleaching do not exist in accessible sources for the current period. Given chalcocite yields roughly twice the dissolved copper of chalcopyrite over an eight-week test, the mineralogy gap is severe.
2. Thermophile scale-up. Thermophilic microbes operating at 45 to 60 degrees Celsius improve chalcopyrite recovery in column and pilot work. Controlling temperature, redox potential, and aeration uniformly across large commercial heaps remains difficult because of heterogeneous permeability and cold-spot formation.
3. In-situ feasibility. The most capital-light concept is also the least proven, held back by permeability, containment, and groundwater stewardship barriers.

Commercial-scale chalcopyrite solutions remain the defining technical gap, and Rio Tinto’s Nuton programme represents the most visible industry attempt to close it, using proprietary microbial consortia and heat management approaches that target the passivation barrier directly.

Peer-reviewed thermophilic chalcopyrite bioleaching research published in 2024 confirms that extremely thermoacidophilic archaea can reduce surface passivation at elevated temperatures, yet the same work underscores the gap between column-scale results and the heterogeneous conditions that characterise full commercial heaps.

The thermophile route is the leading technical answer to passivation, but the same extreme chemistries that dissolve chalcopyrite, sulfate above 120 g/L and dissolved metals up to 20 g/L, also stress the microbial communities doing the work. Promising in a column is not the same as controllable across a full-scale heap.

In-situ bioleaching: the cost argument that does not yet hold up at project scale

In-situ bioleaching stimulates microbial activity inside the ore body without excavation. In theory, that eliminates the massive capital cost of moving and stacking rock.

In practice, three named barriers keep it unfinanceable at commercial scale today: subsurface permeability that cannot be reliably controlled, containment of acidic leach solutions, and decades-long groundwater stewardship obligations. It sits at conceptual or pilot stage.

Treat any in-situ bioleaching claim in a junior mining promotion as a caution flag, not a technology endorsement.

The decisive distinction for you is mineralogy. A copper project marketed on bioleaching economics is a fundamentally different proposition depending on whether the ore is chalcocite or chalcopyrite. If you cannot locate that distinction in the technical report, you are pricing risk you have not read.

Choosing a framework: what method selection signals to an investor evaluating a gold or copper project

Method selection is best read as a diagnostic signal. The extraction route a project uses, and the justification given for it, reveals the team’s assumptions about ore quality, capex tolerance, financing access, and regulatory environment. Four investor-facing scenarios cover most of what you will encounter.

Cyanide remains entrenched in gold for a reason. It is used to process over 90% of hard-rock gold globally, backed by reliability, mature plant design, and codified risk-management frameworks that de-risk projects for operators and lenders alike.

It is worth noting a data gap. No documented commercial case studies from 2023 to 2026 were found comparing cost overruns or permitting outcomes from switching directly between the two methods. That absence reinforces the central point: ore geology dictates the choice before feasibility begins, so method-switching is rarely a live option.

When a junior company cites bioleaching as a cost advantage without ore-type characterisation to back it, treat the omission as a red flag rather than a technical detail you can skip. Method selection is a risk-disclosure item, and it reveals how well a project team understands its own ore body.

What the method question actually tells you about a mining project’s risk profile

The core conclusion is worth stating plainly. Cyanide leaching and bioleaching are not substitutes fighting over the same ore. They are tools shaped for different geological contexts, and your job is to verify that a project’s method actually matches its mineralogy.

Two forces will keep shifting the balance over the coming years. ESG-linked financing conditions are tightening around cyanide, with Lloyds Banking Group’s 2026 stance the leading indicator, while incremental bioleaching advances chip away at chalcopyrite. Neither is a near-term market-disrupting event, but both are directional.

The value here is durable. Extraction method literacy is a repeatable skill that transfers across any gold or copper feasibility document, in any jurisdiction, through any commodity cycle. The ESG narrative without the mineralogy check is precisely how investors get misled by method-selection marketing.

Three questions to carry into any technical report:

• Does the report confirm ore mineralogy before stating its recovery assumptions?
• Does the ESG disclosure address the specific liability category of the chosen method, cyanide Code compliance or acid mine drainage management?
• Is any bioleaching claim anchored in commercially established ore types, such as chalcocite, or in speculative primary-sulfide and in-situ applications?

This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with financial professionals before making investment decisions. Past performance does not guarantee future results, and financial projections are subject to market conditions and various risk factors.